Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article 1 — Zhao et al., VAF-based AML risk stratification (PMID 42085510)
🟢 NEAR_TERM_IMPLEMENTABLE
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Extending ELN 2022 with quantitative VAFs rather than binary mutation calls is a meaningful methodological step; not a wholly new concept but no validated clinical tool exists combining all 7 loci with cytogenetics in this way |
| Clinical Relevance | 8 | Directly refines AML risk stratification for non-transplanted patients; practical impact on therapy intensity decisions today given NGS is already routinely performed |
| Population Reach | 6 | AML is uncommon (~20,000 new US cases/year) but globally significant; limited to non-transplant subgroup further narrows but unmet need is high |
| Implementation Speed | 7 | NGS already embedded in AML workup; VAF thresholds could be layered onto existing reports without new platforms; requires guideline uptake |
| Evidence Strength | 6 | Retrospective + external validation strengthens credibility, but single-center primary cohort, abstract-only access, and unreported external cohort size cap confidence |
Key quantitative result: All pairwise P<0.05 across risk tiers internally and in external cohort; effect sizes not extractable from abstract.
External validation: Yes — external cohort referenced, size unknown.
Main limitation: Single-center primary cohort; retrospective design; external cohort size undisclosed; transplant recipients not stratified (limits utility in that subgroup).
Equity implications: Accessible only where NGS is available — underserves low-resource settings globally. No mention of racial/ethnic subgroup analysis.
Evidence Maturity: Validated ✓ (confirmed)
Original triage_score: 8 | Phase 2 composite: 7.0
Article 2 — Liu et al., Postoperative MRD ctDNA in ESCC (PMID 42086163)
🔴 EARLY_CANCER_DETECTION
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Demonstrates that ctDNA MRD completely supersedes pathologic complete response — a paradigm-shifting finding for ESCC. Prior ctDNA-MRD work in lung and colorectal is more established; ESCC-specific data are sparse |
| Clinical Relevance | 8 | Directly actionable: could redefine adjuvant therapy allocation in post-esophagectomy ESCC, affecting surveillance intensity, chemotherapy decisions, and trial eligibility |
| Population Reach | 5 | ESCC is geographically concentrated (China, Africa, Central Asia); moderate global incidence ~500K/year but rare in Western cohorts — reach is high relative to the specific clinical population |
| Implementation Speed | 5 | Tumor-informed personalized ctDNA assay requires patient-specific tumor sequencing and bespoke panel design; not plug-and-play; prospective validation still needed |
| Evidence Strength | 6 | Post-hoc analysis of a prospective trial is stronger than pure retrospective; HR=13.62 is a striking effect size; N=93 is small; requires prospective confirmatory trial |
Key quantitative result: HR=13.62 (P<0.001) for MRD positivity; 1-year recurrence 3.7% (pCR+MRD-) vs. 82.4% (non-pCR+MRD+); MRD+ vs MRD- overall: 66.7% vs 6.1%.
External validation: No independent external cohort; post-hoc of preSINO trial only.
Main limitation: Small N=93; post-hoc (not pre-specified primary endpoint); single trial, single geographic cohort (China); no OS data reported; tumor-informed assay requires individualized sequencing.
Equity implications: ESCC disproportionately affects lower-income populations in Asia/Africa; tumor-informed ctDNA assay is expensive and infrastructure-dependent — high-burden populations may not benefit near-term.
Evidence Maturity: Validated → revised to Exploratory/Early Validated — prospective confirmation required before this is truly validated; the post-hoc design and N=93 do not meet the bar for "Validated" as I apply it independently.
Original triage_score: 8 | Phase 2 composite: 6.4
Article 3 — Al-Ali et al., MDM2 inhibitors in myeloid cancers (PMID 42086932)
🟠 NOVEL_TREATMENT
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | MDM2-p53 biology is well established; the shift from AML failure to MPN promise is notable, and emerging degrader class is genuinely new |
| Clinical Relevance | 6 | Myelofibrosis has unmet need; however this is a review synthesizing existing trial data — no new clinical data generated |
| Population Reach | 5 | MPN/myelofibrosis: ~50,000–80,000 prevalent US cases; globally rare but severely underserved |
| Implementation Speed | 4 | Degraders are still experimental; combinations need trial validation; JAK inhibitor combinations are nearest to implementation |
| Evidence Strength | 4 | Narrative review — no primary data; evidence quality capped accordingly |
Key quantitative result: Phase III AML trials were negative (specific results not in abstract); MF data show clinical signals (molecular/spleen/symptom responses — quantitative thresholds not extractable).
External validation: N/A (review).
Main limitation: No primary data; abstract only; narrative review risks selective synthesis.
Equity implications: Myelofibrosis treatment is concentrated at academic centers; access disparities significant for rural/low-income patients.
Evidence Maturity: Exploratory ✓ (confirmed)
Original triage_score: 7 | Phase 2 composite: 5.0
Article 4 — Willmann et al., Metastatic Trajectories in NSCLC (PMID 42085620)
🟠 NOVEL_TREATMENT
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Formalizing "metastatic trajectories" as a spatiotemporal lesion-level framework is genuinely novel conceptual architecture; goes beyond existing oligometastatic binary classifications |
| Clinical Relevance | 6 | High potential but currently a conceptual framework — not yet evidence-based therapy guidance; could influence future trial design meaningfully |
| Population Reach | 7 | NSCLC is the world's leading cancer killer; ~2.2M new cases/year globally; framework addresses the majority of NSCLC patients who develop metastases |
| Implementation Speed | 3 | Requires prospective trial validation, standardized reporting infrastructure, validated ctDNA/radiomic platforms — years from clinical adoption |
| Evidence Strength | 3 | Framework/conceptual paper with evidence synthesis — no primary quantitative data; abstract only |
Key quantitative result: None (conceptual paper).
External validation: N/A.
Main limitation: Pure framework — no prospective data; requires validation in randomized trials before influencing clinical decisions.
Equity implications: Radiomics and ctDNA monitoring require advanced imaging infrastructure; limited applicability in low-resource settings where NSCLC burden is also rising.
Evidence Maturity: Exploratory ✓ (confirmed)
Original triage_score: 7 | Phase 2 composite: 5.4
Article 5 — Beydoun et al., Diet Quality, Epigenetic Aging, and Mortality (PMID 42087064)
🟢 NEAR_TERM_IMPLEMENTABLE
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Epigenetic clocks as mediators of diet-mortality associations adds mechanistic specificity; diet-health associations are well-known; the mediation pathway is the novel contribution |
| Clinical Relevance | 6 | Strengthens mechanistic rationale for existing dietary guidance; GrimAge is research-grade, not yet clinical-grade; ~44% mediation is compelling but observational |
| Population Reach | 8 | Dietary intervention affects all US adults and globally; NHANES + HRS are broadly representative US cohorts |
| Implementation Speed | 6 | Dietary advice is immediately actionable; epigenetic clock deployment in clinical settings lags; public health messaging impact is near-term |
| Evidence Strength | 7 | Two independent prospective cohorts; established GrimAge instrument; Bayesian network + GSEM methodology is sophisticated; major limitation is observational causality |
Key quantitative result: GrimAgeEAA HR=1.61/SD (NHANES), HR=1.76/SD (HRS); ~44% mediation of diet-mortality association by epigenetic aging in HRS.
External validation: Yes — two independent cohorts (NHANES, HRS) with consistent findings.
Main limitation: Observational — cannot establish causality between diet, epigenetic aging, and mortality; physical activity confounding attenuates associations.
Equity implications: NHANES includes diverse US populations; dietary quality interventions are less accessible to food-insecure, low-income communities — those potentially at highest risk.
Evidence Maturity: Validated ✓ (confirmed)
Original triage_score: 7 | Phase 2 composite: 6.7
Article 6 — Chopra et al., Australian Frailty Consensus Statement (PMID 42083402)
🟢 NEAR_TERM_IMPLEMENTABLE
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Delphi consensus codifies existing evidence; moderate novelty in the specific Australian context and multicomponent recommendations |
| Clinical Relevance | 8 | Directly implementable national clinical guidance — general practitioners and aged care providers can act on this today |
| Population Reach | 7 | Community-dwelling older adults are a massive population globally; frailty prevalence rises sharply with age; Australia-specific but framework is internationally transferable |
| Implementation Speed | 7 | Consensus statement is designed for immediate adoption; primary care and aged care systems are the delivery mechanism |
| Evidence Strength | 6 | Delphi methodology is appropriate for consensus generation but does not generate new evidence; strength derives from expert synthesis of existing RCT/cohort data |
Key quantitative result: None — consensus recommendations (specific thresholds/metrics require full text).
External validation: N/A (expert consensus process).
Main limitation: Australia-specific; Delphi process can reflect expert opinion rather than data gaps; population health impact depends on implementation fidelity.
Equity implications: Frailty disproportionately affects disadvantaged older adults (lower SES, Indigenous populations); consensus guidelines are only impactful if equitably distributed to community settings — Indigenous Australian populations may face access gaps.
Evidence Maturity: Validated ✓ (confirmed for consensus)
Original triage_score: 7 | Phase 2 composite: 6.5
Article 7 — Lopes et al., cfDNA chromatin profiling in leiomyosarcoma (PMID 42086706)
⚪ PROMISING_PRELIMINARY
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | cfDNA active chromatin profiling as a treatment-predictive tool is technically novel; applying it to LMS immunotherapy response prediction is first-of-kind work |
| Clinical Relevance | 6 | Extremely relevant to a rare cancer population with no reliable immunotherapy predictors; relative to disease population, clinical value is high |
| Population Reach | 3 | Leiomyosarcoma: ~2,000–3,000 new US cases/year; rare disease context — judged relative to unmet need (very high) rather than absolute numbers |
| Implementation Speed | 3 | Aqtual platform is commercial but proprietary; N=30 requires large prospective validation before adoption |
| Evidence Strength | 4 | N=30 exploratory analysis; commercial conflict of interest (Aqtual); abstract only; single-trial subset; no independent replication |
Key quantitative result: Baseline tumor fraction >5% negatively predicted clinical benefit (p=0.041); B/T-cell activation enrichment correlated with improved PFS (quantitative HR not in abstract).
External validation: None.
Main limitation: N=30; commercial bias (Aqtual platform); single-center trial subset; no external replication; abstract only.
Equity implications: Rare cancer with limited specialist center access; if assay is commercialized, cost/insurance access will be major barriers.
Evidence Maturity: Exploratory ✓ (confirmed)
Original triage_score: 7 | Phase 2 composite: 4.7
Article 8 — Chen et al., CCR7/H3K9me3 in B-cell lymphoma (PMID 42086343)
⚪ PROMISING_PRELIMINARY
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | CCR7 as a homing/infiltration marker is known; H3K9me3 epigenetic silencing is established; their mechanistic link and dual prognostic use is novel |
| Clinical Relevance | 5 | Incremental addition to IPI-based risk stratification if validated; IHC is a practicable clinical assay |
| Population Reach | 6 | Aggressive B-cell lymphoma affects ~15,000–20,000 US patients/year; globally common |
| Implementation Speed | 4 | IHC is technically feasible but requires clinical validation and standardization before adoption |
| Evidence Strength | 3 | Unreported sample size; single-center; non-top-tier journal (European Cytokine Network); abstract only; no independent replication |
Key quantitative result: Multivariable Cox regression showing CCR7/H3K9me3 co-expression predicts worse PFS (HR not extractable from abstract).
External validation: None reported.
Main limitation: Sample size unreported; single-center; non-top-tier journal; abstract only.
Equity implications: IHC-based test is relatively low-cost; but standardization across pathology labs in low-resource settings would be a barrier.
Evidence Maturity: Exploratory ✓ (confirmed)
Original triage_score: 6 | Phase 2 composite: 4.7
Article 9 — Jiao et al., 4-gene NGS panel for thyroid cytology (PMID 42083301)
🟢 NEAR_TERM_IMPLEMENTABLE
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Molecular testing for indeterminate thyroid cytology (Bethesda III/IV) is an established concept (Veracyte Afirma, ThyroSeq); 4-gene minimalist panel is a cost-reduction innovation rather than conceptual breakthrough |
| Clinical Relevance | 6 | Addresses a high-volume, clinically significant problem — unnecessary thyroid surgery — with a cost-effective approach; however generalizability to non-Chinese populations uncertain |
| Population Reach | 7 | Indeterminate thyroid cytology is extremely common globally (~15–30% of FNAs); reducing unnecessary surgeries has broad impact |
| Implementation Speed | 5 | NGS panel is technically accessible; regulatory approval and validation in non-Asian populations needed before broader adoption |
| Evidence Strength | 5 | Multicenter design is a strength; medium-confidence classification due to unreported sample size; China-only limits generalizability |
Key quantitative result: Sensitivity/specificity metrics not extractable from abstract; multicenter validation reported.
External validation: Multicenter (multiple Chinese centers) — geographically limited.
Main limitation: China-only cohort; sample size unreported; abstract only; existing validated tools (ThyroSeq, Afirma) set a high comparator bar.
Equity implications: Cost-effectiveness angle is potentially high-impact for LMICs if validated; avoidance of unnecessary surgery benefits patients in systems with high surgical complication rates.
Evidence Maturity: Validated → downgrade to Exploratory/Early Validated pending non-Chinese population data
Original triage_score: 6 | Phase 2 composite: 5.5
Article 10 — Davalos et al., DNA methylation predicts therapy response (PMID 42086381)
⚪ PROMISING_PRELIMINARY
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | DNA methylation-therapy response is an established research area; synthesizing it with liquid biopsy adds forward-looking value; Esteller group is authoritative |
| Clinical Relevance | 5 | No new clinical data; review of existing evidence; actionability limited until assays are prospectively validated |
| Population Reach | 8 | Cross-cancer applicability; methylation profiling relevant to the entire oncology population |
| Implementation Speed | 3 | Standardized assays not yet available; prospective trial validation needed |
| Evidence Strength | 3 | Narrative review only; no primary data |
Evidence Maturity: Exploratory ✓ (confirmed)
Original triage_score: 6 | Phase 2 composite: 5.2
Article 11 — Guardo et al., ML for long COVID identification (PMID 42086912)
⚪ PROMISING_PRELIMINARY
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Multi-scale ML for condition identification is established methodology; long COVID ML models are an active area |
| Clinical Relevance | 5 | Long COVID affects millions globally; diagnostic identification has real value; modest AUC gain (+0.012) limits immediate clinical utility |
| Population Reach | 8 | ~65M estimated global long COVID cases; broad population relevance |
| Implementation Speed | 4 | Multi-scale data integration (EHR + survey + genomics) adds practical friction; authors themselves note modest gain may not justify cost |
| Evidence Strength | 7 | Large N=17,200; NIH All of Us diverse cohort; rigorous ML validation; retrospective design is appropriate for this question |
Key quantitative result: AUC 0.748 (multi-scale) vs. 0.736 (EHR-only); ΔAUCs = 0.012 (modest).
External validation: Internal train/test split; external cohort not mentioned in abstract.
Main limitation: Modest AUC gain; retrospective; external validation cohort absent; long COVID definition heterogeneity.
Equity implications: All of Us has strong diversity representation — equity is a design feature; however, survey+genomics integration requires patient engagement that may underserve populations with limited healthcare access.
Evidence Maturity: Exploratory ✓ (confirmed)
Original triage_score: 6 | Phase 2 composite: 5.8
Article 12 — Chen et al., TACE + immunotherapy for HCC (PMID 42086291)
⬜ STANDARD
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | EMERALD-1 and LEAP-012 data are known; the novel contribution is the precision stratification framework synthesis |
| Clinical Relevance | 7 | HCC intermediate stage is common; TACE + immunotherapy combinations are entering practice; OS inconsistency is an important safety/efficacy signal |
| Population Reach | 7 | HCC is the 6th most common cancer globally; intermediate stage represents ~30–40% of HCC patients |
| Implementation Speed | 5 | TACE combinations are already being used; ctDNA/biomarker stratification is the lagging component |
| Evidence Strength | 4 | Narrative review only; relies on trial data (EMERALD-1, LEAP-012) which are separately published; review quality adds interpretive value only |
Evidence Maturity: Potentially Practice-Changing ✓ (confirmed at the underlying trial level, not the review itself)
Original triage_score: 6 | Phase 2 composite: 5.7
Article 13 — Torres-Mayo et al., Gut microbiota and immunometabolism in obesity (PMID 42083504)
⬜ STANDARD
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | mTOR/AMPK immunometabolic reprogramming by gut microbiota metabolites synthesized in obesity context is current and adds mechanistic depth |
| Clinical Relevance | 5 | No direct clinical tools; framework for microbiota-targeted interventions |
| Population Reach | 8 | Obesity affects >1 billion globally |
| Implementation Speed | 2 | Microbiota-based interventions are early-stage; translation gap is large |
| Evidence Strength | 3 | Narrative review; mainly animal/mechanistic data |
Evidence Maturity: Exploratory ✓ (confirmed)
Original triage_score: 6 | Phase 2 composite: 4.9
Article 14 — Mohamed Naim et al., Conjunctival vessel segmentation in diabetes (PMID 42086622)
⚪ PROMISING_PRELIMINARY
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Topology-preserving DL for conjunctival vessel segmentation is a genuinely novel technical approach to non-invasive microvascular phenotyping |
| Clinical Relevance | 5 | Proof-of-concept; requires clinical validation comparing to established retinal imaging standards |
| Population Reach | 8 | Diabetes affects >500M globally; scalable non-invasive screening tool has massive reach potential |
| Implementation Speed | 4 | Requires device standardization, regulatory approval, clinical validation |
| Evidence Strength | 4 | Unreported sample size; single-center Sri Lanka; abstract only; no clinical comparator head-to-head |
Evidence Maturity: Exploratory ✓ (confirmed)
Original triage_score: 6 | Phase 2 composite: 5.5
Article 15 — Usso et al., Cervical Cancer Screening in Ethiopia (PMID 42083273)
🟡 UNDERSERVED_POPULATION
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Screening utilization meta-analyses are common; Ethiopian-specific focus is modestly novel |
| Clinical Relevance | 6 | Directly identifies a screening gap in a high-burden population; actionable for health policy |
| Population Reach | 7 | Sub-Saharan Africa carries disproportionate cervical cancer burden; health worker focus leverages change-agent potential |
| Implementation Speed | 6 | Systematic review findings can immediately inform screening program design and health worker education |
| Evidence Strength | 5 | Systematic review + meta-analysis design is strong for this question; sample sizes of included studies unknown; abstract only |
Equity implications: Explicitly addresses one of the highest-burden, most underserved cervical cancer populations globally — high equity value.
Evidence Maturity: Exploratory ✓ (confirmed — describes current state, does not validate an intervention)
Original triage_score: 6 | Phase 2 composite: 5.5
Article 16 — Ben Lamine et al., Hematologic irAEs and disease recurrence (PMID 42086953)
⚪ PROMISING_PRELIMINARY
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Reframing hematologic irAEs as potential positive predictive biomarkers is a genuinely interesting hypothesis for the hematology-oncology field |
| Clinical Relevance | 5 | Currently hypothesis-generating; if validated, could directly affect irAE management decisions |
| Population Reach | 5 | Hematolymphoid malignancy immunotherapy patients are a growing but specific population |
| Implementation Speed | 3 | Prospective validation required before clinical adoption |
| Evidence Strength | 3 | Perspective/narrative review; observational evidence basis only |
Evidence Maturity: Exploratory ✓ (confirmed)
Original triage_score: 5 | Phase 2 composite: 4.5
Article 17 — Wu et al., Melatonin for late-onset hypogonadism (PMID 42083130)
⬜ STANDARD
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Framing melatonin as a Leydig cell senescence-targeting agent (not just a sleep supplement) is novel; mechanism-based rationale is well-developed |
| Clinical Relevance | 3 | Mainly preclinical; no RCT evidence; hypothesis only at this stage |
| Population Reach | 6 | Aging men globally — LOH is common; but clinical actionability is distant |
| Implementation Speed | 2 | Clinical trials not yet started in this specific indication |
| Evidence Strength | 2 | Narrative review; primarily preclinical data; no primary clinical trial data |
Evidence Maturity: Exploratory ✓ (confirmed)
Original triage_score: 5 | Phase 2 composite: 3.8
Article 18 — Yuan et al., Model-informed oligonucleotide therapeutics (PMID 42083118)
⬜ STANDARD
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | MIDD frameworks for drug development are established; oligonucleotide application adds specificity |
| Clinical Relevance | 4 | Indirectly relevant — accelerates drug development pipeline for rare disease patients |
| Population Reach | 4 | Rare disease focus is niche but unmet need is high |
| Implementation Speed | 3 | FDA perspective adds regulatory credibility; methodological guidance is implementable by drug developers |
| Evidence Strength | 4 | FDA-affiliated authorship lends authority; narrative review limits evidence grade |
Evidence Maturity: Exploratory ✓ (confirmed)
Original triage_score: 5 | Phase 2 composite: 3.9
Article 19 — Zhou et al., Spatial/Volumetric GBM characteristics (PMID 42083734)
⬜ STANDARD
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Spatial/volumetric MRI features in GBM are a known prognostic domain; incremental refinement |
| Clinical Relevance | 5 | GBM has high unmet need; imaging biomarkers could improve prognostic communication and trial stratification |
| Population Reach | 4 | GBM is rare (~13,000 US cases/year) |
| Implementation Speed | 4 | MRI is widely available; volumetric analysis increasingly automated |
| Evidence Strength | 4 | Retrospective; sample size unreported; abstract only |
Evidence Maturity: Exploratory ✓ (confirmed)
Original triage_score: 5 | Phase 2 composite: 4.4
Article 20 — Hu, Chemokine strategies for CAR-T in solid tumors (PMID 42085851)
⚪ PROMISING_PRELIMINARY
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Chemokine-guided CAR-T infiltration is an active area; comprehensive chemokine-class organization is useful; incremental over existing reviews |
| Clinical Relevance | 4 | Primarily preclinical; some early clinical data mentioned but CAR-T in solid tumors remains pre-adoption |
| Population Reach | 7 | Solid tumors are the dominant cancer burden; if CAR-T can be extended to solid tumors, population reach is enormous |
| Implementation Speed | 2 | Multiple engineering and regulatory barriers; years from broad adoption |
| Evidence Strength | 3 | Single-author narrative review; mainly preclinical; abstract only |
Evidence Maturity: Exploratory ✓ (confirmed)
Original triage_score: 5 | Phase 2 composite: 4.5
PHASE 3 — Ranking
Composite Impact Score Formula
Clinical Relevance (30%) + Population Reach (25%) + Scientific Novelty (20%) + Implementation Speed (15%) + Evidence Strength (10%)
| Rank | Article | Flag | Impact Score | Clinical Rel. (30%) | Pop. Reach (25%) | Sci. Novelty (20%) | Impl. Speed (15%) | Evid. Strength (10%) | Triage Score | Study Design |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Zhao et al. — VAF-based AML risk stratification (PMID 42085510) | 🟢 | 6.75 | 8 | 6 | 7 | 7 | 6 | 8 | Retrospective cohort + external validation |
| 2 | Beydoun et al. — Diet, epigenetic aging, mortality (PMID 42087064) | 🟢 | 6.50 | 6 | 8 | 6 | 6 | 7 | 7 | Prospective two-cohort (NHANES + HRS) |
| 3 | Liu et al. — ctDNA MRD in ESCC (PMID 42086163) | 🔴 | 6.35 | 8 | 5 | 8 | 5 | 6 | 8 | Post-hoc of prospective preSINO trial |
| 4 | Chopra et al. — Australian frailty consensus (PMID 42083402) | 🟢 | 6.30 | 8 | 7 | 4 | 7 | 6 | 7 | Modified Delphi consensus |
| 5 | Willmann et al. — Metastatic trajectories in NSCLC (PMID 42085620) | 🟠 | 5.60 | 6 | 7 | 8 | 3 | 3 | 7 | Conceptual framework + evidence synthesis |
| 6 | Guardo et al. — ML for long COVID (PMID 42086912) | ⚪ | 5.55 | 5 | 8 | 5 | 4 | 7 | 6 | Retrospective ML development + validation |
| 7 | Chen et al. — TACE + immunotherapy for HCC (PMID 42086291) | ⬜ | 5.55 | 7 | 7 | 5 | 5 | 4 | 6 | Narrative review (EMERALD-1, LEAP-012) |
| 8 | Jiao et al. — 4-gene NGS panel thyroid (PMID 42083301) | 🟢 | 5.50 | 6 | 7 | 5 | 5 | 5 | 6 | Multicenter diagnostic validation |
| 9 | Mohamed Naim et al. — Conjunctival vessel segmentation (PMID 42086622) | ⚪ | 5.45 | 5 | 8 | 7 | 4 | 4 | 6 | Prospective observational + ML |
| 10 | Usso et al. — Cervical cancer screening Ethiopia (PMID 42083273) | 🟡 | 5.40 | 6 | 7 | 4 | 6 | 5 | 6 | Systematic review + meta-analysis |
| 11 | Davalos et al. — DNA methylation therapy response (PMID 42086381) | ⚪ | 5.15 | 5 | 8 | 6 | 3 | 3 | 6 | Narrative review |
| 12 | Al-Ali et al. — MDM2 inhibitors in myeloid cancers (PMID 42086932) | 🟠 | 5.00 | 6 | 5 | 6 | 4 | 4 | 7 | Narrative review |
| 13 | Torres-Mayo et al. — Gut microbiota/immunometabolism in obesity (PMID 42083504) | ⬜ | 4.90 | 5 | 8 | 6 | 2 | 3 | 6 | Narrative review |
| 14 | Lopes et al. — cfDNAac profiling in leiomyosarcoma (PMID 42086706) | ⚪ | 4.70 | 6 | 3 | 8 | 3 | 4 | 7 | Exploratory biomarker analysis |
| 15 | Chen et al. — CCR7/H3K9me3 in B-cell lymphoma (PMID 42086343) | ⚪ | 4.70 | 5 | 6 | 6 | 4 | 3 | 6 | Retrospective cohort (IHC + mechanistic) |
| 16 | Hu — Chemokine strategies for CAR-T (PMID 42085851) | ⚪ | 4.50 | 4 | 7 | 6 | 2 | 3 | 5 | Narrative review |
| 17 | Ben Lamine et al. — Hematologic irAEs and recurrence (PMID 42086953) | ⚪ | 4.50 | 5 | 5 | 6 | 3 | 3 | 5 | Clinical perspective/narrative review |
| 18 | Zhou et al. — Spatial/Volumetric GBM (PMID 42083734) | ⬜ | 4.40 | 5 | 4 | 4 | 4 | 4 | 5 | Retrospective cohort (imaging) |
| 19 | Yuan et al. — Oligonucleotide MIDD (PMID 42083118) | ⬜ | 3.90 | 4 | 4 | 4 | 3 | 4 | 5 | Narrative review (FDA perspective) |
| 20 | Wu et al. — Melatonin for late-onset hypogonadism (PMID 42083130) | ⬜ | 3.80 | 3 | 6 | 6 | 2 | 2 | 5 | Narrative review (preclinical) |
Rank Justifications
#1 — Zhao et al. (VAF-based AML): This retrospective cohort with external validation earns the top rank through the combination of high clinical relevance, near-term implementation potential, and credible scientific novelty. Routine NGS is already embedded in AML diagnostic workups, meaning quantitative VAF thresholds for seven key mutations can be layered onto existing workflows without new platforms or assays. The external validation — even with its undisclosed size — provides confidence beyond single-center findings. The targeted population (non-transplanted AML patients) has clear unmet need for better risk stratification beyond binary ELN 2022 mutation status. It meets the Evidence Strength ≥6 threshold needed to rank #1.
Why it matters: Every AML patient who receives risk stratification with binary "mutation present/absent" data is currently missing quantitative information already captured in their NGS report. This study provides a validated roadmap to extract that information.
#2 — Beydoun et al. (Diet, epigenetic aging, mortality): Two independent, well-characterized prospective cohorts (NHANES + HRS) with the gold-standard GrimAgeEAA clock and sophisticated mediation methodology. The finding that ~44% of the diet-mortality benefit is mediated through epigenetic aging mechanisms provides a mechanistic bridge that strengthens existing dietary public health guidance. High population reach across the entire US adult population, combined with the near-term implementability of dietary advice, gives this a strong composite score. Physical activity confounding is a meaningful limitation that prevents higher evidence strength scoring.
Why it matters: Eating better may be slowing your biological clock — not just metaphorically. This adds the strongest mechanistic support to date for diet-quality interventions as an aging intervention, not just a cardiometabolic one.
#3 — Liu et al. (ctDNA MRD in ESCC): The HR of 13.62 for MRD positivity predicting recurrence-free survival is one of the most striking effect sizes in this batch. More importantly, MRD status completely superseded pathologic complete response — the current standard — on multivariable analysis, which is a paradigm-challenging finding. The post-hoc nature of the analysis and N=93 prevent higher rankings, and a downgrade from "Validated" to "Early Validated" is appropriate. Tumor-informed ctDNA assay design also creates implementation friction. The 🔴 flag is retained — this is genuinely important for early cancer recurrence detection.
Why it matters: A patient achieving pathologic complete response after chemoradiotherapy for esophageal cancer may still have an 40% recurrence rate if they're ctDNA-positive — meaning the current gold standard is blind to the patients most at risk.
#4 — Chopra et al. (Australian frailty consensus): National consensus guidance has immediate clinical reach that original research does not. The Modified Delphi process codifies evidence across screening, nutrition, physical activity, polypharmacy, and multidisciplinary care coordination for a population whose burden is growing rapidly worldwide. Scored lower on novelty than the top three, but its implementation speed and direct patient care applicability push it to #4. Internationally transferable despite the Australian primary focus.
Why it matters: Frailty is preventable and reversible in its early stages — a national consensus statement gives every GP and aged care provider a clear, evidence-endorsed action plan.
#5–#20: Remaining articles span frameworks, reviews, and preliminary exploratory studies. Notable watchlist items:
- Lopes et al. cfDNAac in LMS (PMID 42086706) (#14): Scores low due to N=30 and commercial conflict, but the scientific novelty (8/10) and unmet need in a chemotherapy-resistant rare cancer make it a high-priority watchlist item. Prospective validation would rapidly move this higher.
- Guardo et al. long COVID ML (PMID 42086912) (#6): Large and rigorous, but the modest AUC gain limits clinical utility relative to its methodological quality.
- Usso et al. cervical cancer screening Ethiopia (PMID 42083273) (#10, 🟡): Highest equity value in the batch. The population reach relative to unmet need is exceptional; this should inform regional screening program design immediately.
Conflicting Evidence Note
No direct head-to-head conflicts exist in this batch. However, articles #1 (AML VAF) and #2 (ESCC ctDNA) both argue for refinements to post-treatment molecular risk stratification — using different methodologies (quantitative NGS VAF vs. tumor-informed ctDNA). These are complementary rather than conflicting approaches, operating in different tumor types and clinical moments (diagnosis vs. post-surgical). Both are constrained by the same structural limitation: retrospective single-center primary cohorts with smaller-than-ideal external validation.